BACKGROUND: A medical need exists for successfully treating patients afflicted with leukemia and especially those that relapse and ultimately become refractory to front line chemotherapies. Leukemia cases are particularly high within Hispanic populations where this disease is among the most frequently occurring cancer. A possible cause is somatic mutations in Janus tyrosine kinase (Jak3). Fourteen somatic mutations have been reported in Jak3, including M511I and A573V, from patients with various forms of leukemia. While several of these Jak3 mutations have been shown to possess transforming ability in cell lines, whether these mutations are susceptible to Jak3 selective inhibitors remains less clear. METHODS: The IL-3 dependent pro-B cell line Ba/F3 was virally transduced with plasmids encoding GFP and different mutant forms of Jak3, some of which conferred IL-3 independence. Sensitivity to pre-clinical and clinical Jak3 selective inhibitors was assessed for cellular viability and growth. RESULTS: Two Jak3 mutations conferred IL-3 independent growth in Ba/F3 cells. However, the level of drug sensitivity varied with respect to Jak3 inhibitors NC1153, CP-690,550, and EP-009. CONCLUSION: Jak3 inhibitors CP-690,550 and NC1153 showed efficacy in reducing viability of Ba/F3 cells transformed with mutant forms of Jak3, thus providing new therapeutic strategies to treat these types of cancer.
BACKGROUND: A medical need exists for successfully treating patients afflicted with leukemia and especially those that relapse and ultimately become refractory to front line chemotherapies. Leukemia cases are particularly high within Hispanic populations where this disease is among the most frequently occurring cancer. A possible cause is somatic mutations in Janus tyrosine kinase (Jak3). Fourteen somatic mutations have been reported in Jak3, including M511I and A573V, from patients with various forms of leukemia. While several of these Jak3 mutations have been shown to possess transforming ability in cell lines, whether these mutations are susceptible to Jak3 selective inhibitors remains less clear. METHODS: The IL-3 dependent pro-B cell line Ba/F3 was virally transduced with plasmids encoding GFP and different mutant forms of Jak3, some of which conferred IL-3 independence. Sensitivity to pre-clinical and clinical Jak3 selective inhibitors was assessed for cellular viability and growth. RESULTS: Two Jak3 mutations conferred IL-3 independent growth in Ba/F3 cells. However, the level of drug sensitivity varied with respect to Jak3 inhibitors NC1153, CP-690,550, and EP-009. CONCLUSION:Jak3 inhibitors CP-690,550 and NC1153 showed efficacy in reducing viability of Ba/F3 cells transformed with mutant forms of Jak3, thus providing new therapeutic strategies to treat these types of cancer.
Entities:
Keywords:
Janus tyrosine kinase; acute lymphoblastic leukemia; signal transducer and activator of transcription; tyrosine kinase inhibitor
Authors: Jessica L Barrington-Trimis; Myles Cockburn; Catherine Metayer; W James Gauderman; Joseph Wiemels; Roberta McKean-Cowdin Journal: Blood Date: 2015-05-07 Impact factor: 22.113
Authors: Zsuzsanna S Nagy; Jeremy A Ross; Georgialina Rodriguez; Julia Bader; Jonathan Dimmock; Robert A Kirken Journal: FEBS Lett Date: 2010-03-06 Impact factor: 4.124
Authors: Ghee Chong Koo; Soo Yong Tan; Tiffany Tang; Song Ling Poon; George E Allen; Leonard Tan; Soo Ching Chong; Whee Sze Ong; Kevin Tay; Miriam Tao; Richard Quek; Susan Loong; Kheng-Wei Yeoh; Swee Peng Yap; Kuo Ann Lee; Lay Cheng Lim; Daryl Tan; Christopher Goh; Ioana Cutcutache; Willie Yu; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Hong Lee Heng; Anna Gan; Choon Kiat Ong; Steve Rozen; Patrick Tan; Bin Tean Teh; Soon Thye Lim Journal: Cancer Discov Date: 2012-06-15 Impact factor: 39.397
Authors: James D Wilkinson; Alex Gonzalez; Brad Wohler-Torres; Lora E Fleming; Jill MacKinnon; Edward Trapido; Jaclyn Button; Steven Peace Journal: Rev Panam Salud Publica Date: 2005-07
Authors: Sandrine Degryse; Charles E de Bock; Luk Cox; Sofie Demeyer; Olga Gielen; Nicole Mentens; Kris Jacobs; Ellen Geerdens; Valentina Gianfelici; Gert Hulselmans; Mark Fiers; Stein Aerts; Jules P Meijerink; Thomas Tousseyn; Jan Cools Journal: Blood Date: 2014-09-05 Impact factor: 22.113
Authors: Jonathan Wong; Meaghan Wall; Gregory Philip Corboy; Nadine Taubenheim; Gareth Peter Gregory; Stephen Opat; Jake Shortt Journal: Cold Spring Harb Mol Case Stud Date: 2020-08-25